Orris

Aetiology and management of dilated left atrium , moderate MR (PML is thickened & restricted)

Reading File
Finding Sources
Finding Sources
Searching PubMed

"Mitral Valve Insufficiency"[MeSH Terms] AND management

Searching the Web

2025 ESC EACTS guidelines valvular heart disease chronic primary mitral regurgitation follow up moderate

Finding Sources
Finding Sources
Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC13128274

Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"Rheumatic Heart Disease"[MeSH Terms] AND "Mitral Valve Insufficiency"[MeSH Terms]

A dilated left atrium (LA) with moderate mitral regurgitation (MR) and a thickened, restricted posterior mitral leaflet (PML) suggests that the MR is likely primary/organic, rather than simply due to annular dilatation.

Most likely aetiology

1. Rheumatic mitral valve disease

This is the leading consideration if there is leaflet thickening, restricted movement, chordal thickening/fusion or shortening, commissural fusion, or coexistent mitral stenosis.
  • Rheumatic disease often causes leaflet fibrosis and retraction, especially affecting the posterior leaflet and subvalvular apparatus.
  • It can produce mixed mitral disease: MR with varying degrees of mitral stenosis.
  • The LA enlarges over time because of chronic MR, any associated mitral stenosis, and atrial fibrillation.
A thick and restricted PML may represent Carpentier type IIIa leaflet dysfunction if restriction occurs in both systole and diastole, classically seen in rheumatic disease.

2. Mitral annular calcification

More likely in older people or those with chronic kidney disease. Calcium involving the posterior annulus or PML can restrict PML mobility and cause MR, sometimes with associated mitral stenosis.

3. Previous infective endocarditis

Healed endocarditis can leave leaflet thickening, scarring, perforation, or retraction. Consider this if there was fever, bacteremia, embolic events, intravenous drug use, or a prior history of endocarditis.

4. Functional MR with leaflet tethering

If the left ventricle is dilated or has regional wall-motion abnormalities, especially inferior/posterior infarction, the PML may be tethered and restricted in systole, termed Carpentier type IIIb. This would be secondary MR, driven by LV remodeling rather than primary leaflet pathology.

5. Less common causes

  • Congenital mitral valve abnormality
  • Prior mitral valve surgery or chest radiotherapy
  • Autoimmune/inflammatory valvulitis
  • Drug-related valve disease, depending on exposure history
MR itself causes chronic LA volume overload and enlargement. Other contributors to LA enlargement should also be sought: atrial fibrillation, hypertension with diastolic dysfunction, mitral stenosis, obesity/sleep apnea, and cardiomyopathy. Chronic MR with a compliant enlarged LA may cause fewer early pulmonary symptoms but still predisposes to atrial fibrillation and thromboembolism. Braunwald’s Heart Disease, p. 1463.

Essential evaluation

A cardiology review and a high-quality transthoracic echo are needed, with transoesophageal echo, preferably 3D, if the mechanism or severity is unclear.
The report should document:
  • MR severity by an integrated approach: vena contracta, EROA, regurgitant volume/fraction, pulmonary-vein flow, jet characteristics
  • Mitral valve area and mean transmitral gradient, to exclude associated mitral stenosis
  • PML morphology: mobility in systole and diastole, calcification, chordal thickening/fusion, prolapse, perforation, tethering
  • LV size and function, including LVEF and LV end-systolic dimension
  • LA volume index
  • Pulmonary artery systolic pressure
  • Right ventricular function and tricuspid regurgitation
  • ECG or ambulatory monitoring for atrial fibrillation
  • Blood pressure, ischemia assessment if relevant, and consideration of cardiac MRI when LV function/scar or MR quantification remains uncertain
Transoesophageal echo is particularly useful when detailed leaflet anatomy is needed for repair planning or when transthoracic imaging is inconclusive. The 2025 ESC/EACTS guideline update also emphasizes multimodality imaging and specialist Heart Team assessment for complex valve disease.

Management

If MR is truly moderate and the patient is stable

In most cases, no mitral procedure is indicated solely for moderate MR.
Management is usually:
  1. Regular surveillance
    • Clinical assessment and repeat echocardiography, commonly every 1-2 years for stable moderate MR, sooner if symptoms develop, the murmur changes, LV/LA size increases, pulmonary pressure rises, or imaging is uncertain.
    • Follow-up should be individualized by the cardiologist, particularly if rheumatic mixed mitral disease is present.
  2. Treat contributors
    • Good blood-pressure control.
    • Treat heart failure or LV dysfunction with guideline-directed therapy if present.
    • Treat ischemic heart disease if it is causing LV remodeling and functional MR.
    • Manage sleep apnea, obesity, and other contributors to raised filling pressures.
  3. Atrial fibrillation management
    • Rate or rhythm control according to symptoms and clinical context.
    • Assess stroke risk and prescribe anticoagulation when indicated.
    • If there is moderate-to-severe rheumatic mitral stenosis, anticoagulation for AF is generally with a vitamin K antagonist such as warfarin, not a DOAC.
  4. Rheumatic disease management, if confirmed
    • Assess for prior acute rheumatic fever and ongoing exposure risk.
    • Secondary antibiotic prophylaxis may be indicated in patients with a history of rheumatic fever and persistent valvular disease. Duration depends on age, recurrence risk, severity, and local rheumatic-heart-disease guidance. Harrison’s notes that persistent rheumatic valvular disease often warrants prolonged, sometimes lifelong, secondary prophylaxis. Harrison’s Principles of Internal Medicine, p. 2902.
  5. Endocarditis prevention
    • Maintain excellent dental hygiene and obtain prompt assessment for unexplained fever.
    • Routine antibiotic prophylaxis before dental procedures is not recommended for native-valve MR alone. It is reserved for selected highest-risk cardiac conditions.

When to refer for intervention

Refer early to a valve center/Heart Team if MR progresses to severe, if repairability is uncertain, or if there is mixed mitral stenosis and regurgitation.
Intervention becomes relevant in severe primary MR with any of the following:
  • Symptoms attributable to MR
  • LV systolic dysfunction or progressive LV enlargement
  • New atrial fibrillation
  • Pulmonary hypertension
  • Need for another cardiac operation
  • Progressive structural deterioration despite few symptoms
For durable primary MR repair, surgical mitral repair is preferred when feasible. In rheumatic valves, repair may be technically harder and replacement is sometimes necessary because of leaflet and subvalvular fibrosis. A recent meta-analysis of rheumatic mitral surgery found that the repair-versus-replacement decision must be individualized to valve anatomy and likelihood of a durable repair (PMID 38518844).
Important: if there is concomitant mitral stenosis, balloon mitral valvotomy is generally unsuitable when MR is already more than mild, because it can worsen regurgitation.

Seek urgent assessment if there is

  • New or worsening breathlessness, orthopnea, pulmonary edema
  • Palpitations with dizziness/syncope
  • New atrial fibrillation
  • Chest pain
  • Fever with worsening murmur or embolic symptoms
  • Falling exercise tolerance, leg swelling, or hemoptysis
The key next step is to determine whether the PML restriction is rheumatic/scar-related, calcific, or due to LV tethering, and whether there is any associated mitral stenosis. That mechanism determines prognosis and whether surveillance, medical treatment, or valve intervention is appropriate.
This is a shared conversation. Sign in to Orris to start your own chat.